TL;DR
This study found that inactivated COVID-19 vaccines do not significantly increase seizure frequency in patients with epilepsy (PWE). While overall seizure frequency tended to decrease post-vaccination, juvenile PWE showed a less pronounced decrease and warrant closer observation. The findings suggest that "uncontrolled epilepsy" shouldn't be a strict contraindication for vaccination, and patients should maintain their anti-seizure medication regimen.
What Problem Does This Paper Address?
The COVID-19 pandemic and the subsequent rollout of vaccines presented a dilemma for individuals with epilepsy (PWE). Many COVID-19 vaccines listed "uncontrolled epilepsy" as a contraindication, leading to vaccine hesitancy and restricted access for a vulnerable population. While COVID-19 itself can potentially trigger seizures, the safety of vaccines in PWE remained unclear, with some prior studies suggesting a potential for seizure exacerbation. This paper aims to provide robust evidence on the safety and impact of inactivated COVID-19 vaccines on seizure frequency in PWE, addressing the critical need for clear guidelines to facilitate informed vaccination decisions.
Methods
This was a prospective, multicenter, self-controlled study involving 859 patients with epilepsy recruited from 25 centers across China. Seizure frequency was meticulously recorded at three time points: one month before the first vaccination, one month after the first dose, and one month after the second dose. A generalized linear mixed-effects model (GLMM) with a Poisson error structure was employed for statistical analysis. This approach allowed for the modeling of seizure frequency while accounting for individual patient variability and the clustered nature of the data (by center and subject). The study also collected data on various potential influencing factors, including age, epilepsy etiology, seizure type, duration of epilepsy, anti-seizure medication (ASM) use, and time since the last seizure before vaccination.
Datasets
The study utilized data collected from 859 patients with epilepsy across 25 epilepsy centers in China. This dataset was prospectively gathered and included detailed information on seizure frequency, patient demographics, epilepsy characteristics, and vaccination status. No new benchmark datasets were introduced.
Key Insights and Ideas
- Vaccine Safety in PWE: The primary takeaway is that inactivated COVID-19 vaccines appear to be safe for the majority of PWE, with no significant increase in seizure frequency observed. This challenges the broad contraindication of "uncontrolled epilepsy."
- Seizure Frequency Trend: Interestingly, seizure frequency tended to decrease after vaccination in both adults and juveniles, though the effect was more pronounced in adults. This suggests that factors beyond just the vaccine itself might be at play, potentially including improved medical attention during the study period or a "time effect."
- Juvenile PWE Require Closer Monitoring: While generally safe, juvenile PWE showed a less significant decrease in seizure frequency compared to adults, indicating they may be a more vulnerable group and warrant closer observation post-vaccination.
- ASM Regimen is Crucial: The study strongly advises against reducing anti-seizure medication (ASM) dosage during the peri-vaccination period, as this could potentially increase seizure risk.
- Etiology Matters: Patients with hereditary epilepsy showed a higher risk of increased seizure frequency after vaccination compared to those with unknown etiology.
- Time Since Last Seizure (ILSFV) is a Predictor: A shorter interval since the last seizure before vaccination was associated with a higher likelihood of seizure frequency changes post-vaccination.
Key Results
- Out of 859 patients, 3.6% and 4.1% experienced increased seizure frequency after the first and second doses, respectively.
- Adults showed an 81% decrease in seizure frequency after the first dose and an 85% decrease after the second dose compared to baseline.
- Juveniles (<18) showed a 25% decrease after the first dose and a 51% decrease after the second dose.
- The reduction in seizure frequency was significantly more pronounced in adults than in juveniles.
- 25.3% of patients reported non-epileptic adverse reactions, which were generally mild and did not include serious events like Guillain-Barré syndrome or anaphylactic shock.
Limitations and Future Work
- Vaccine Type: The study primarily focused on inactivated COVID-19 vaccines used in China. Findings may not be directly generalizable to mRNA or adenovirus vector vaccines, which have different safety and efficacy profiles.
- Immune Etiology: Patients with epilepsy due to immune causes were excluded, limiting the study's scope.
- Seizure Frequency Reporting: Seizure data relied on patient reports, which can be subject to recall bias or subjective interpretation.
- High Seizure Frequency: The study excluded patients with extremely frequent and unstable seizures, and the maximum seizure frequency observed was 24/month, meaning results might not fully apply to individuals with very severe epilepsy.
Future work could involve investigating the safety of other vaccine types in PWE, exploring the mechanisms behind the observed seizure frequency decrease, and developing more precise parameters for "uncontrolled epilepsy" to guide vaccination decisions. Further research on juvenile PWE and those with hereditary epilepsy is also warranted.
Summary updated